Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business UpdatesGlobeNewsWire • 03/05/25
Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should KnowZacks Investment Research • 02/17/25
Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking CheapSeeking Alpha • 02/05/25
Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/12/24
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus ErythematosusGlobeNewsWire • 12/09/24
Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment OptionsSeeking Alpha • 11/20/24
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR ConvergenceGlobeNewsWire • 11/18/24
Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business UpdatesGlobeNewsWire • 11/12/24
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual MeetingGlobeNewsWire • 11/09/24
Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual MeetingGlobeNewsWire • 11/08/24
Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report?Zacks Investment Research • 09/12/24
All You Need to Know About Fate Therapeutics (FATE) Rating Upgrade to BuyZacks Investment Research • 08/16/24
FATE Q2 Earnings Beat on Lower Expenses, Collaboration Revenues GrowZacks Investment Research • 08/14/24
Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business UpdatesGlobeNewsWire • 08/13/24
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?The Motley Fool • 07/21/24
FATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Fate Therapeutics, Inc. (NASDAQ: FATE) and Encourages Long-Term FATE Investors to Contact the FirmPRNewsWire • 06/13/24